Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Lynx1 Capital Management LP. Insider active across 5 companies, notably TScan Therapeutics, Inc.. Cumulatively, 19 reports have been logged. Split: 18 buys · 1 sell. Total volume traded: €11.1m. Activity tracked since 31 May 2023. The latest transaction was filed on 6 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Lynx1 Capital Management LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10,000 shares@ US$2.51481.5% of flowCommon stock, $0.0001 par value per share Common StockSEC:0000902664-23-003407:0
19 of 19 declarations
About Lynx1 Capital Management LP
Lynx1 Capital Management LP has filed 17 filings in total. In the 17 sampled recent filings, the reported transactions are mostly acquisitions, with buys of EUR 10993296 and sells of EUR 23513 between 2023-06-02 and 2026-04-02. The companies named in these filings are Cullinan Therapeutics, Inc., TScan Therapeutics, Inc., Passage BIO, Inc., Korro Bio, Inc., where the entity is listed as 10% Owner, and Neuphoria Therapeutics Inc.